Reyhan Akhtar1, Shammy Chandel1, Pooja Sarotra1, Bikash Medhi1. 1. Reyhan Akhtar, Shammy Chandel, Pooja Sarotra, Bikash Medhi, Department of Pharmacology, Postgraduate Institute of Medical Education and Research, Chandigarh 160012, India.
Abstract
AIM: To review the clinical trials for the development in drugs for chemotherapeutic treatment of colorectal cancer (CRC). METHODS: A systematic review identified randomized controlled trials (RCTs) assessing drugs for the treatment of CRC or adenomatous polyps from www.clinicaltrials.gov. Various online medical databases were searched for relevant publications. RESULTS: Combination treatment regimens of standard drugs with newer agents have been shown to improve overall survival, disease-free survival, time to progression and quality of life compared to that with standard drugs alone in patients with advanced colorectal cancer. The FOLFOXIRI regimen has been associated with a significantly higher response rate, progression-free survival and overall survival compared to the FOLFIRI regimen. CONCLUSION: Oxaliplatin plus intravenous bolus fluorouracil and leucovorin has been shown to be superior for disease-free survival when compared to intravenous bolus fluorouracil and leucovorin. In addition, oxaliplatin regimens were more likely to result in successful surgical resections. First line treatment with cetuximab plus fluorouracil, leucovorin and irinotecan has been found to reduce the risk of metastatic progression in patients with epidermal growth factor receptor-positive colorectal cancer with unresectable metastases. The addition of bevacizumab has been shown to significantly increase overall and progression-free survival when given in combination with standard therapy.
AIM: To review the clinical trials for the development in drugs for chemotherapeutic treatment of colorectal cancer (CRC). METHODS: A systematic review identified randomized controlled trials (RCTs) assessing drugs for the treatment of CRC or adenomatous polyps from www.clinicaltrials.gov. Various online medical databases were searched for relevant publications. RESULTS: Combination treatment regimens of standard drugs with newer agents have been shown to improve overall survival, disease-free survival, time to progression and quality of life compared to that with standard drugs alone in patients with advanced colorectal cancer. The FOLFOXIRI regimen has been associated with a significantly higher response rate, progression-free survival and overall survival compared to the FOLFIRI regimen. CONCLUSION:Oxaliplatin plus intravenous bolus fluorouracil and leucovorin has been shown to be superior for disease-free survival when compared to intravenous bolus fluorouracil and leucovorin. In addition, oxaliplatin regimens were more likely to result in successful surgical resections. First line treatment with cetuximab plus fluorouracil, leucovorin and irinotecan has been found to reduce the risk of metastatic progression in patients with epidermal growth factor receptor-positive colorectal cancer with unresectable metastases. The addition of bevacizumab has been shown to significantly increase overall and progression-free survival when given in combination with standard therapy.
Authors: Neal J Meropol; Philip J Gold; Robert B Diasio; Michael Andria; Mandeep Dhami; Thomas Godfrey; Albert J Kovatich; Kirk A Lund; Edith Mitchell; Roland Schwarting Journal: J Clin Oncol Date: 2006-09-01 Impact factor: 44.544
Authors: Jeffrey A Meyerhardt; Andrew X Zhu; Peter C Enzinger; David P Ryan; Jeffrey W Clark; Matthew H Kulke; Craig C Earle; Michele Vincitore; Ann Michelini; Susan Sheehan; Charles S Fuchs Journal: J Clin Oncol Date: 2006-04-20 Impact factor: 44.544
Authors: M Koopman; N F Antonini; J Douma; J Wals; A H Honkoop; F L G Erdkamp; R S de Jong; C J Rodenburg; G Vreugdenhil; J M Akkermans-Vogelaar; C J A Punt Journal: Ann Oncol Date: 2006-07-27 Impact factor: 32.976
Authors: Scott R Steele; Grace E Park; Eric K Johnson; Matthew J Martin; Alexander Stojadinovic; J A Maykel; Marlin W Causey Journal: Dis Colon Rectum Date: 2014-03 Impact factor: 4.585
Authors: Eric Van Cutsem; Roberto Labianca; György Bodoky; Carlo Barone; Enrique Aranda; Bernard Nordlinger; Claire Topham; Josep Tabernero; Thierry André; Alberto F Sobrero; Enrico Mini; Richard Greil; Francesco Di Costanzo; Laurence Collette; Laura Cisar; Xiaoxi Zhang; David Khayat; Carsten Bokemeyer; Arnaud D Roth; David Cunningham Journal: J Clin Oncol Date: 2009-05-18 Impact factor: 44.544
Authors: Jordan Berlin; James Posey; Simon Tchekmedyian; Eddie Hu; David Chan; Imtiaz Malik; Liqiang Yang; Rafael G Amado; J Randolph Hecht Journal: Clin Colorectal Cancer Date: 2007-03 Impact factor: 4.481
Authors: Wentian Wang; Lu Zhang; Lorraine Morlock; Noelle S Williams; Jerry W Shay; Jef K De Brabander Journal: J Med Chem Date: 2019-05-09 Impact factor: 7.446
Authors: Sumit Basu; Min Zeng; Taijun Yin; Song Gao; Ming Hu Journal: J Chromatogr B Analyt Technol Biomed Life Sci Date: 2016-02-09 Impact factor: 3.205
Authors: Ksenia Martchenko; Irene Schmidtmann; Thomas Thomaidis; Verena Thole; Peter R Galle; Marc Becker; Markus Möhler; Thomas C Wehler; Carl C Schimanski Journal: World J Gastroenterol Date: 2016-06-21 Impact factor: 5.742
Authors: Sarah Theiner; Christoph Kornauth; Hristo P Varbanov; Markus Galanski; Sushilla Van Schoonhoven; Petra Heffeter; Walter Berger; Alexander E Egger; Bernhard K Keppler Journal: Metallomics Date: 2015-04-09 Impact factor: 4.526